Stimuvax Cancer Vaccine Phase III Study Begins
Tue, 27 Feb 2007 08:00 AM EST
... Merck KGaA today announced that the first patient has been enrolled in its global Phase III clinical study, START (Stimulating Targeted Antigenic Responses To NSCLC), assessing the efficacy and safety of Stimuvax (BLP25 liposome vaccine) as a potential treatment for patients with unresectable stage III non-small cell lung cancer (NSCLC). [click link for full article] ...
Related Topics
- Vaccine
- Polio Vaccine & Cancer
- Prostate Cancer
- Antithrombin III
- Polio Vaccine
- Cervical Cancer
- Polio Vaccine & Origin of HIV/AIDS
- Kidney Cancer
- Thyroid Cancer
- Clinical Trials
- Vaccine Side Effects
- MMR Vaccine & (Asceptic) Meningitis
- Smallpox Vaccine
- Chickenpox Vaccine
- Cancers
- Melanoma
- Hepatitis A Vaccine
- Hepatitis A and Hepatitis B Vaccine
- Familial Dysautonomia
- Brain Cancer

Not Signed In -

